Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.

@article{Mulkay2001LongtermTA,
  title={Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.},
  author={J P Mulkay and Hubert Louis and Vincent Donckier and Nadine Bourgeois and Michael Adler and Jacques Devi{\'e}re and Olivier Le Moine},
  journal={Acta gastro-enterologica Belgica},
  year={2001},
  volume={64 1},
  pages={15-9}
}
BACKGROUND Hepatorenal syndrome (HRS) is a severe complication of liver cirrhosis. Recently, ornipressin, a potent splanchnic vasoconstrictor, was reported to improve renal function in patients with HRS. However, this treatment is associated with a high incidence of vascular complications. Terlipressin is thought to be as effective as ornipressin with less systemic complications. AIMS To evaluate the effectiveness and safety of terlipressin administration in cirrhotic patients with type 1 HRS… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

Hepatorenal syndrome

Nature Reviews Disease Primers • 2018

Protecting the Kidney in Liver Transplant Candidates: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons • 2016
View 3 Excerpts

Similar Papers

Loading similar papers…